LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Accueil・Liste d'Actions・Emergent BioSolutions Inc

Emergent BioSolutions Inc

Fermé

SecteurSoins de santé

8.55 -5.84

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.51

Max

9.08

Chiffres clés
By Trading Economics
Revenu	61M 6.8M
Ventes	7.4M 156M
P/E Moyenne du Secteur	8.634 50.102
BPA	0.21
Marge bénéficiaire	4.356
Employés	900
EBITDA	28M 35M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+31.58% upside

Dividendes
By Dow Jones
Prochains Résultats	5 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	21M 436M
Ouverture précédente	14.39
Clôture précédente	8.55

Sentiment de l'Actualité

By Acuity

62%

38%

281 / 344 Classement par Healthcare

Emergent BioSolutions Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 juin 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 juin 2026, 23:38 UTC

Acquisitions, Fusions, Rachats

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 juin 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 juin 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 juin 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 juin 2026, 22:08 UTC

Acquisitions, Fusions, Rachats

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 juin 2026, 22:01 UTC

Acquisitions, Fusions, Rachats

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 juin 2026, 22:01 UTC

Acquisitions, Fusions, Rachats

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 juin 2026, 21:55 UTC

Acquisitions, Fusions, Rachats

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 juin 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 juin 2026, 21:22 UTC

Market Talk

Acquisitions, Fusions, Rachats

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 juin 2026, 20:50 UTC

Market Talk

Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

1 juin 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 juin 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1 juin 2026, 20:46 UTC

Acquisitions, Fusions, Rachats

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 juin 2026, 20:22 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 juin 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 juin 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Declares $11 Special Div

1 juin 2026, 20:20 UTC

Acquisitions, Fusions, Rachats

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 juin 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 juin 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 juin 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 juin 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 juin 2026, 18:54 UTC

Acquisitions, Fusions, Rachats

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 juin 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 juin 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1 juin 2026, 18:00 UTC

Acquisitions, Fusions, Rachats

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 juin 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 juin 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 juin 2026, 17:10 UTC

Market Talk

Acquisitions, Fusions, Rachats

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Comparaison

Variation de prix

Emergent BioSolutions Inc prévision

Objectif de Prix

By TipRanks

31.58% hausse

Prévisions sur 12 Mois

Moyen 12 USD 31.58%

Haut 12 USD

Bas 12 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

Achat

Maintien

Vente

Basé sur 1 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

281 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.